Amyloid and tau: the two proteins behind most Alzheimer's headlines, explained simply.
These two proteins are mentioned constantly in Alzheimer's research, but they are rarely explained in plain language. Here is what they are, what changes in disease, and what we can measure today.
Amyloid plaques accumulate between brain cells, while tau tangles develop inside them. These changes can begin many years before symptoms. Blood biomarkers can now help detect Alzheimer's-related pathology, but on their own they do not predict a person's cognitive future.
Most clients pay $0 with employer sponsored insurance.
What amyloid beta actually is
Amyloid beta is a protein fragment produced when a larger protein called APP (amyloid precursor protein) is broken down. Amyloid has many important functions in the brain and is constantly being produced. Normally, amyloid proteins are cleared from the brain and don't cause any issues. In Alzheimer's disease, certain forms accumulate and form plaques between neurons. These plaques are one of the biological hallmarks of the disease.
What tau actually is
Tau is a protein that helps support the internal structure of neurons. In Alzheimer's, as a result of things like amyloid accumulation or inflammation, tau becomes abnormally phosphorylated, loses its normal function, and forms tangles inside neurons. Tau burden tends to track cognitive symptoms more closely than amyloid burden does.
That is one reason newer blood tests often measure phosphorylated tau fragments such as pTau-217.
The long pre-symptom window
Alzheimer's-related biological changes can begin many years before cognitive symptoms become obvious, and these can often be measured on a brain scan or blood test. But that does not mean everyone with a biomarker change will develop dementia. It means the biology and the symptoms do not start at the same time.
For prevention-focused care, this long window matters because many factors associated with long-term brain health, including blood pressure, lipids, blood sugar, physical activity, hearing, and sleep, can be addressed well before symptoms occur.
Can amyloid plaques be removed?
The strongest evidence for directly lowering amyloid comes from anti-amyloid medications used in people with diagnosed early Alzheimer's disease. These drugs can reduce amyloid plaque burden, but they are prescription treatments with important risks and are not general prevention tools.
Lifestyle is a more interesting and less settled question. We do not have randomized evidence showing that a particular diet, supplement, exercise plan, or lifestyle protocol reliably removes existing amyloid plaques in people without diagnosed disease.
There are, however, individual reports and emerging prevention research showing that Alzheimer's-related biomarkers can change. Those observations are encouraging, but they are not proof that a specific lifestyle program “clears plaques.”
One BetterBrain member, “Joan” (name changed for privacy), came to the program at 59 with a family history of dementia and an elevated pTau-217 result, along with high inflammation and elevated ApoB and Lp(a). Her plan was not aimed at pTau alone. It included clinician-directed treatment, lipid management, Zone 2 cycling, and cognitive stimulation. At her 90-day follow-up, BetterBrain reported improved memory and processing speed, a 28% reduction in ApoB, and pTau-217 moving into a less concerning range.
This is one member case, not a clinical trial. It cannot tell us which intervention caused the changes or whether another person would see the same result. What it illustrates is why BetterBrain reads Alzheimer's-related pathology alongside the rest of a person's biology rather than treating pTau-217 as a standalone answer.
What the evidence says
Amyloid is important, but it is not the whole story. Some people have elevated amyloid biomarkers while remaining cognitively normal for years. Tau, vascular health, inflammation, and other factors add context.
Sleep appears to support brain waste clearance. Research on glymphatic function suggests that sleep is an important part of the brain's clearance systems, including for clearing amyloid. The exact relationship between sleep and Alzheimer's risk is still an active area of research, though those with consistently short or poor sleep do have an increased risk.
What you can measure today
The main ways to assess Alzheimer's-related amyloid or tau biology include PET imaging, cerebrospinal fluid testing, and increasingly blood-based biomarkers such as pTau-217.
At BetterBrain, pTau-217 is an optional add-on. The core panel focuses on the broader modifiable picture, including vascular, metabolic, inflammatory, and nutritional markers.
Most clients pay $0 with employer sponsored insurance.
Common questions
Do amyloid plaques mean Alzheimer's?
Amyloid plaques are a hallmark of Alzheimer's biology, but biomarker positivity alone does not tell you whether or when symptoms will develop.
Can you test for amyloid and tau without a brain scan?
Partly. Blood biomarkers such as pTau-217 can indicate that Alzheimer's-related changes are likely present, but they are not a direct measure of amyloid or tau in the brain. As with any test, some people with a higher pTau-217 will have less amyloid or tau on a scan, and vice versa. PET imaging and spinal fluid testing remain the direct measures.
Does everyone develop amyloid with age?
Most people who live long enough will accumulate some amyloid. Amyloid positivity becomes more common with age, and it does not always correspond to cognitive impairment.
The biology can start early. So can the work of protecting brain health.
You cannot control every part of Alzheimer's biology, but many of the factors associated with how the brain ages are measurable and modifiable years before symptoms appear.